Coherus Oncology, Inc.
NASDAQ:CHRSBiotechnology
+$0.03 today
- Market cap
- $63.35M
- Beta
- 0.96
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$1.11
Volume 2.55M
Average 1.15M
CHRS Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Coherus Oncology, Inc.NASDAQ: CHRS
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures outflow grows to $0
Q1 FY2026 capital expenditures was $0, compared with $0 a year earlier. Trailing-twelve-month capital expenditures was $0.
Context
- Capital expenditures amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Capital expenditures increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly capital expenditures holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | +100.0% |
| FY2023 | 2023-12-31 | (286K) | +86.0% |
| FY2022 | 2022-12-31 | (2.04M) | -58.2% |
| FY2021 | 2021-12-31 | (1.29M) | — |
Capital Expenditures vs competitors
How CHRS compares with its peers on the latest reported figures
- CHRS's LTM Mar 2026 capital expenditures of $0 is the 9th largest of the 11 companies compared; the peer median is $489K.
- Capital expenditures amounts to 0.0% of revenue for CHRS, versus a peer median of 1.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $3.49M | +602.4% | -9.8% | 179.1% |
| LTM Mar 2026 | $3.39M | -23.5% | -18.7% | 4.3% | |
| LTM Mar 2026 | $737K | +411.8% | -55.0% | 1.3% | |
| LTM Mar 2026 | $671K | +272.8% | -52.0% | 1.9% | |
| LTM Mar 2026 | $523K | -54.8% | -68.0% | 1.8% | |
| LTM Mar 2026 | $455K | -54.0% | +37.7% | 0.6% | |
| LTM Mar 2026 | $115K | -56.9% | -82.8% | 0.3% | |
| LTM Mar 2026 | $50K | -53.3% | -7.8% | — | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding CHRS) | $489K | -38.4% | -35.3% | 1.6% | |
Competitors are the stored peer set for CHRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (287.1M) | (291.75M) | (237.89M) | 28.51M | 168.02M |
| Depreciation & Amortization | 3.45M | 3.7M | 3.79M | 5.28M | 3.92M |
| Deferred Income Tax | 9.44M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 51.36M | 50.74M | 43.11M | 27.8M | 16.97M |
| Change in Working Capital | 42.36M | (79.26M) | (36.83M) | 55.89M | (5.84M) |
| Accounts Receivables | 34.06M | 13.05M | (150.68M) | 149.35M | 93.56M |
| Inventory | (6.25M) | (47.35M) | (46.73M) | (31.95M) | (17.11M) |
| Accounts Payables | 874K | (4.55M) | 23.76M | (3.94M) | (19.56M) |
| Other Working Capital | 13.68M | (40.41M) | 136.83M | (57.57M) | (62.74M) |
| Other Non-Cash Items | 143.05M | 75.45M | 52.93M | (137.92M) | (321.59M) |
| Operating Cash Flow | (37.43M) | (241.12M) | (174.88M) | (20.44M) | (138.51M) |
| Capital Expenditures | (1.29M) | (2.04M) | (286K) | 0 | 0 |
| Acquisitions (Net) | 1.29M | 0 | 845K | 0 | 0 |
| Purchases of Investments | (182.49M) | (127.38M) | (19.51M) | 0 | (103.84M) |
| Sales of Investments | 181.36M | 0 | 157.64M | 14.89M | 21.46M |
| Other Investing Activities | (137.29M) | (37.43M) | 5.95M | 215.43M | 457.46M |
| Investing Cash Flow | (138.41M) | (166.85M) | 144.64M | 230.32M | 375.09M |
| Debt Repayment | (672K) | 49.93M | 0 | (223.41M) | (233.19M) |
| Common Stock Issued | 40.9M | 6.36M | 74.22M | 1.46M | 8.25M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 54.3M | (1.96M) | (4.62M) | 34.98M | (48.77M) |
| Financing Cash Flow | 51.88M | 54.33M | 69.6M | (186.97M) | (273.71M) |
| Effect of Forex Changes | 0 | 0 | (12K) | 0 | 0 |
| Net Change in Cash | (123.96M) | (353.65M) | 39.34M | 22.91M | (37.13M) |
| Free Cash Flow | (38.72M) | (243.16M) | (175.17M) | (20.44M) | (138.51M) |
Coherus Oncology, Inc.
NASDAQ:CHRS
Intrinsic Alpha fair value
Locked
Current Price
$0.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.